Research Article

Association of the PPARγ2 gene Pro12Ala variant with primary hypertension and metabolic lipid disorders in Han Chinese of Inner Mongolia

Published: July 06, 2010
Genet. Mol. Res. 9 (3) : 1312-1320 DOI: 10.4238/vol9-3gmr833

Abstract

In order to determine whether Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 (PPARγ2) gene contributes to susceptibility to primary hypertension and metabolic lipid disorders, 482 unrelated subjects from Inner Mongolia were studied, including 137 healthy normotensive (controls) and 345 hypertensive subjects. PCR-RFLP was used to determine the genotypes of Pro12Ala variants of the PPARγ2 gene, and direct sequencing was used to check the results. The frequency of the Ala allele was lower in patients with hypertension (1.3%) than in controls (3.6%). The incidence of the Ala allele was significantly lower in patients with hypertension (P = 0.018) and in those with elevated blood lipids (P = 0.040), compared to the control group. Total plasma cholesterol, triglycerides and high-density lipoprotein cholesterol were significantly higher (P

In order to determine whether Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 (PPARγ2) gene contributes to susceptibility to primary hypertension and metabolic lipid disorders, 482 unrelated subjects from Inner Mongolia were studied, including 137 healthy normotensive (controls) and 345 hypertensive subjects. PCR-RFLP was used to determine the genotypes of Pro12Ala variants of the PPARγ2 gene, and direct sequencing was used to check the results. The frequency of the Ala allele was lower in patients with hypertension (1.3%) than in controls (3.6%). The incidence of the Ala allele was significantly lower in patients with hypertension (P = 0.018) and in those with elevated blood lipids (P = 0.040), compared to the control group. Total plasma cholesterol, triglycerides and high-density lipoprotein cholesterol were significantly higher (P

About the Authors